BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
Details
News Market Reaction – BIOA
On Feb 20, the first trading day after this news, BIOA closed 1.84% above the previous close.
Data tracked by StockTitan Argus for the Feb 20 session.
Key Figures
- Conference dates
- February 25–26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Fireside chat date
- Thursday, February 26
- Scheduled speaking slot at Oppenheimer conference
- Presentation time
- 10:40 AM–11:05 AM ET
- Duration of CEO fireside chat at conference
- Webcast archive period
- 30 days
- Replay availability in investor section of company website
- Current share price
- $20.09
- Price prior to conference presentation news
- Price vs 52-week high
- -16.29%
- Distance from 52-week high of $24.00 before this news
- Price vs 52-week low
- 597.57%
- Gain from 52-week low of $2.88 before this news
- Daily move
- 0.41%
- 24-hour price change on article date
Historical Context
-
Announced timing and access details for upcoming quarterly earnings presentation.
-
Reported Leqembi Q4 2025 sales and associated royalty growth versus prior year.
-
Priced upsized $115M equity offering at $19.50 per share under S-3 registration.
-
Announced proposed public equity offering with additional underwriter option and use of proceeds.
-
Expanded BGE‑102 into DME with planned Phase 1b/2a trial and mid‑2027 readout.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026.
Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.